CBU
ESPR

CIBC Bancorp USA’s Esperion Therapeutics ESPR Stock Holding History

CIBC Bancorp USA’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$44.2K Buy
13,978
+1,847
+15% +$5.17K ﹤0.01% 1897
2026
Q1 		$33.2K Buy
+12,131
New +$38.4K ﹤0.01% 1725
2025
Q3 		$56.4K Buy
+21,286
New +$41.2K ﹤0.01% 1407

Other funds holding ESPR

GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.16B AUM 43.32% 1-Year Est. Return

CIBC Bancorp USA's ESPR Position: Q2 2026 in Review

CIBC Bancorp USA increased its Esperion Therapeutics (ESPR) stake by 15% in Q2 2026, buying an estimated $5.17K and bringing the position to 13,978 shares worth $44.2K. The position accounts for ﹤0.01% of the portfolio, ranked #1897.

CIBC Bancorp USA first reported a position in ESPR in Q3 2025 and has held it in 3 quarters since. The position peaked at $56.4K in Q3 2025. 191 funds tracked by Wall St. Rank hold ESPR as of Q2 2026.

  • CIBC Bancorp USA held 13,978 shares of Esperion Therapeutics worth $44.2K as of Q2 2026.
  • CIBC Bancorp USA bought 1,847 Esperion Therapeutics shares in Q2 2026, an estimated $5.17K.
  • Esperion Therapeutics made up ﹤0.01% of CIBC Bancorp USA's portfolio in Q2 2026, its #1897 holding.
  • CIBC Bancorp USA first reported a position in Esperion Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • CIBC Bancorp USA's Esperion Therapeutics position peaked at $56.4K in Q3 2025.
  • 191 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2026.

Based on CIBC Bancorp USA's 13F filing for Q2 2026, filed 13 Aug 2026.